Allergic rhinitis is a condition that causes nasal inflammation and congestion in response to allergens such as pollen, dust mites and animal dander. Common symptoms include sneezing, runny nose, nasal congestion and itchy eyes. The global allergic rhinitis treatment market is majorly driven by the rising prevalence of allergic rhinitis around the world. According to studies, over 150 million individuals across the globe suffer from allergic rhinitis. Additionally, factors such as growing environmental pollution levels, increasing stress levels and changing climate are contributing to the rising incidence of allergic diseases.

The global allergic rhinitis treatment market is estimated to be valued at US$ 20.94 Billion in 2024 and is expected to exhibit a CAGR of 9.0% over the forecast period 2024 to 2031.

Key Takeaways

Key players operating in The Allergic Rhinitis Treatment Market are ABB, Emerson Electric Co., Honeywell International, Inc., Kawasaki Heavy Industries, Ltd., Mitsubishi Electric Corporation, OMRON Corporation, Rockwell Automation, Inc., and Schneider Electric.

The global allergic rhinitis treatment market is expected to witness lucrative growth opportunities due to the rising investments by pharmaceutical companies in research and development of innovative therapeutic drugs and devices. Initiatives undertaken by various governments and non-profit organizations to raise awareness about allergic rhinitis diagnosis and management are also creating high potential opportunities in the market.

Leading pharmaceutical companies such as ABB, Emerson Electric Co. and Honeywell International, Inc. are expanding their presence globally through strategic partnerships and acquisitions to cater to the increasing demand for allergic rhinitis treatment worldwide. In the coming years, major players are likely to focus on establishing manufacturing and distribution facilities in emerging economies with high disease prevalence to strengthen their market position internationally.

Market Drivers

According to the National Health Interview Survey in 2017, an estimated 19.2 million American adults reported current doctor-diagnosed seasonal allergies. This large patient pool suffering from the condition is the primary driver boosting demand for various allergic rhinitis treatment medications and devices. Moreover, rising environmental pollution leading to increased sensitization to indoor and outdoor allergens is contributing significantly to the growing patient base. Another major driver is the availability of various effective treatment options, both pharmaceutical and non-pharmaceutical, for allergic rhinitis management which encourages patients to seek proper treatment instead of neglecting symptoms.

Market Restraints

Factors like the preference for alternative traditional medicines over conventional treatment in developing regions and the shortage of allergy specialists in some parts of the world pose challenges for market players. Additionally, the availability of generic equivalents of major drugs at lower costs compared to branded products also restrains market revenue growth to some extent. Lastly, lack of awareness about allergic rhinitis, its causes, and available treatment options, especially in rural areas, is a key market restraint.

Segment Analysis
Allergic rhinitis treatment market comprises antihistamines, intranasal corticosteroids, decongestants, leukotriene receptor antagonists, and antibody immunotherapies. Antihistamines sub segment is dominating as it is the most common OTC treatment for controlling allergy symptoms like sneezing, runny nose and itchy eyes. Antihistamines help to block the action of histamine, a chemical released by the body during an allergic reaction. They are easy available without prescription and affordable for people suffering from mild to moderate allergic rhinitis.

Global Analysis
North America region dominates the allergic rhinitis treatment market owing to high prevalence of allergic rhinitis. According to Asthma and Allergy Foundation of America, nearly 50 million Americans suffer from allergic rhinitis. High disposable income and existence of well-developed healthcare infrastructure in the region are also supporting the market growth. Asia Pacific is expected to growth at fastest pace during forecast period due to increasing pollution levels, changing lifestyle patterns and growing health awareness in emerging countries like China and India. Rising patient population along with growing geriatric population susceptible to allergies will augment the market growth in Asia Pacific region.

Get More Insights On Allergic Rhinitis Treatment Market